- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06846671
Een studie van BGB-16673 vergeleken met de keuze van de onderzoeker bij deelnemers met chronische lymfocytaire leukemie die eerder werd blootgesteld aan zowel bruton tyrosinekinase (BTK) als B-cel leukemie/lymfoom 2-eiwit (BCL2) remmers (BCL2) remmers (BCL2) remmers (BCL2) -remmers (BCL2) (CaDAnCe-302)
Een fase 3, open-label, gerandomiseerde studie van BGB-16673 vergeleken met de keuze van de onderzoeker (iDelalisib plus rituximab of bendamustine plus rituximab of venetoclax plus rituximab-terugtaling) bij patiënten met chronische lymfocyemie die eerder werden blootgesteld aan zowel BTK als BCL2-rempels
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, weight loss and fever. They have shorter life expectancy compared to healthy people. There is an urgent need for new treatment to prolong life and control disease-related symptoms.
In this study, participants with relapsed/refractory (R/R) CLL who were previously exposed to a BTKi and a BCL2i will receive tacabrutideg or the investigator's choice of idelalisib plus rituximab (for CLL only) or bendamustine plus rituximab or venetoclax plus rituximab retreatment. The main purpose of this study is to compare the length of time that participants live without their CLL or SLL worsening between those participants who receive tacabrutideg versus the investigator's choice of treatment (idelalisib plus rituximab or bendamustine plus rituximab, or venetoclax plus rituximab).
Approximately 250 participants will be included in this study around the world. Participants will be randomly allocated to receive either tacabrutideg or the investigator's choice of treatment.
"Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website."
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Study Director
- Telefoonnummer: 1.877.828.5568
- E-mail: clinicaltrials@beonemed.com
Studie Locaties
-
-
-
Caba, Argentinië, CP1114
- Werving
- FUNDALEU
-
Caba, Argentinië, C1431
- Werving
- CEMIC
-
Caba, Argentinië, 1425
- Werving
- Hospital Aleman
-
Ciudad Autonoma Buenos Aires, Argentinië, 1413
- Werving
- Hospital Italiano de Buenos Aires
-
Ciudad Autonoma Buenos Aires, Argentinië, 1426
- Werving
- Instituto Alexander Fleming (Iaf)
-
San Miguel de Tucumán, Argentinië, 4000
- Werving
- Cice 9 de Julio Sanatorio 9 de Julio
-
-
-
-
New South Wales
-
Concord, New South Wales, Australië, NSW 2139
- Werving
- Concord Repatriation General Hospital
-
Gosford, New South Wales, Australië, NSW 2250
- Werving
- Gosford Hospital
-
Port Macquarie, New South Wales, Australië, NSW 2444
- Werving
- Port Macquarie Base Hospital
-
Randwick, New South Wales, Australië, NSW 2031
- Werving
- Prince of Wales Hospital
-
-
Queensland
-
Toowoomba, Queensland, Australië, QLD 4350
- Werving
- Toowoomba Hospital
-
-
South Australia
-
Bedford PK, South Australia, Australië, SA 5042
- Werving
- Flinders Medical Centre
-
-
Victoria
-
Melbourne, Victoria, Australië, VIC 3004
- Werving
- The Alfred Hospital
-
-
Western Australia
-
West Perth, Western Australia, Australië, WA 6005
- Werving
- Perth Blood Institute
-
-
-
-
-
Belo Horizonte, Brazilië, 30110-022
- Werving
- CETUS
-
Brasília, Brazilië, 70200-730
- Werving
- Hospital Sirio Libanes Brasilia
-
Curitiba, Brazilië, 81520-060
- Werving
- Hospital Erasto Gaertner
-
Florianópolis, Brazilië, 88020-210
- Werving
- Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
-
Joinville, Brazilië, 89201-260
- Werving
- Instituto Joinvilense de Hematologia E Oncologia
-
Niterói, Brazilië, 24020-096
- Werving
- Complexo Hospitalar de Niteroi
-
Porto Alegre, Brazilië, 90110-270
- Werving
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Rio de Janeiro, Brazilië, 22250-040
- Werving
- Oncoclinicas Rio de Janeiro Sa
-
Rio de Janeiro, Brazilië, 22061-080
- Werving
- Hospital Sao Lucas Dasa Oncologia
-
Salvador, Brazilië, 41253-190
- Werving
- Hospital Sao Rafael (Rede Dor)
-
São Paulo, Brazilië, 05652-900
- Werving
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brazilië, 04014-002
- Werving
- Instituto Brasileiro de Controle Do Cancer
-
São Paulo, Brazilië, 01401-004
- Werving
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
Vitória, Brazilië, 29043-260
- Werving
- Hospital Santa Rita de Cassia Afecc
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Werving
- Juravinski Cancer Centre
-
London, Ontario, Canada, N6A 5W9
- Werving
- London Health Sciences Centre
-
Ottawa, Ontario, Canada, K1H 8L6
- Werving
- The Ottawa Hospital Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Werving
- Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
-
Montreal, Quebec, Canada, QC H3t 1E2
- Werving
- Jewish General Hospital
-
SaintJerome, Quebec, Canada, J7Z 5T3
- Werving
- Unite de Recherche Clinique Du Cisss Des Laurentides
-
-
-
-
-
Augsburg, Duitsland, 86156
- Werving
- Universitatsklinikum Augsburg
-
Berlin, Duitsland, 10715
- Werving
- Praxis Am Volkspark
-
Chemnitz, Duitsland, 09116
- Werving
- Klinikum Chemnitz Ggmbh
-
Essen, Duitsland, 45122
- Werving
- Universitatsklinikum Essen (Aor)
-
Frankfurt am Main, Duitsland, 60389
- Werving
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Freiburg im Breisgau, Duitsland, 79106
- Werving
- Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
-
Hamburg, Duitsland, 20251
- Werving
- Universitatsklinikum Hamburg Eppendorf
-
Heidelberg, Duitsland, 69120
- Werving
- Universitatsklinikum Heidelberg
-
Homburg, Duitsland, 66421
- Werving
- Universitatsklinikum Des Saarlandes
-
Koblenz, Duitsland, 56068
- Werving
- Invo Institut Fur Versorgungsforschung in Der Onkologie
-
Leipzig, Duitsland, 04103
- Werving
- Universitaetsklinikum Leipzig Aor
-
Münster, Duitsland, 48149
- Werving
- Universitatsklinikum Munster Medizinische Klinik A
-
-
-
-
-
Bari, Italië, 70124
- Werving
- Irccs Istituto Tumori Giovanni Paolo Ii
-
Florence, Italië, 50134
- Werving
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, Italië, 20132
- Werving
- Ospedale San Raffaele
-
Milan, Italië, 20122
- Werving
- Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
-
Naples, Italië, 80131
- Werving
- Azienda Ospedaliera Universitaria Federico Ii
-
Novara, Italië, 28100
- Werving
- Aou Maggiore Della Carita
-
Pavia, Italië, 27100
- Werving
- Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
-
Perugia, Italië, 6129
- Werving
- Ospedale Santa Maria Della Misericordia
-
Roma, Italië, 00168
- Werving
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Kumamoto, Japan, 860-8556
- Werving
- Kumamoto University Hospital
-
Okayama, Japan, 701-1192
- Werving
- National Hospital Organization Okayama Medical Center
-
Osaka, Japan, 545-8586
- Werving
- Osaka Metropolitan University Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Werving
- Aichi Cancer Center Hospital Clinical Oncology
-
-
Chiba
-
Chiba, Chiba, Japan, 260-8717
- Werving
- Chiba Cancer Center
-
-
Ehime
-
Matsuyama, Ehime, Japan, 791-0280
- Werving
- Nho Shikoku Cancer Center
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japan, 730-8619
- Werving
- Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 064-0804
- Werving
- Aiiku Hospital
-
-
Hyōgo
-
AmagasakiCity, Hyōgo, Japan, 660-8550
- Werving
- Hyogo Prefectural Amagasaki General Medical Center
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japan, 890-8520
- Werving
- Kagoshima University Hospital
-
-
Kyoto
-
KyotoShi, Kyoto, Japan, 602-8566
- Werving
- University Hospital, Kyoto Prefectural Univ of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Werving
- Tohoku University Hospital
-
-
Niigata
-
Niigata, Niigata, Japan, 951-8520
- Werving
- Niigata University Medical and Dental Hospital
-
-
Okayama-ken
-
Kurashikishi, Okayama-ken, Japan, 710-8602
- Werving
- Kurashiki Central Hospital
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1191
- Werving
- Kansai Medical University Hospital
-
Sakai, Osaka, Japan, 590-0197
- Werving
- Kindai University Hospital
-
-
Saitama
-
Kawagoeshi, Saitama, Japan, 350-8550
- Werving
- Saitama Medical Center
-
-
Tokyo
-
Bunkyoku, Tokyo, Japan, 113-8677
- Werving
- Tokyo Metropolitan Komagome Hospital
-
Shinagawaku, Tokyo, Japan, 141-0022
- Werving
- Ntt Medical Center Tokyo
-
-
-
-
-
Amsterdam, Nederland, 1081 HV
- Werving
- Amsterdam Umc Vu Mc
-
-
-
-
-
Brzozów, Polen, 36-200
- Werving
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, Polen, 40-519
- Werving
- Pratia Onkologia Katowice
-
Krakow, Polen, 30-727
- Werving
- Pratia McM Krakow
-
Lodz, Polen, 93-513
- Werving
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
-
Lublin, Polen, 20-090
- Werving
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, Polen, 50-367
- Werving
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Brno, Tsjechië, 625 00
- Werving
- Fakultni Nemocnice Brno
-
Hradec Králové, Tsjechië, 500 03
- Werving
- Fakultni Nemocnice Hradec Kralove
-
Ostrava, Tsjechië, 708 00
- Werving
- Fakultni Nemocnice Ostrava
-
Prague, Tsjechië, 10000
- Werving
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
-
Ankara, Turkije (Türkiye), 6500
- Werving
- Gazi University
-
Ankara, Turkije (Türkiye), 06200
- Werving
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
-
Balçova, Turkije (Türkiye), 35330
- Werving
- Dokuz Eylul University
-
Dokuma, Turkije (Türkiye), 07025
- Werving
- Antalya Memorial Hospital
-
Sakarya, Turkije (Türkiye), 54100
- Werving
- Sakarya Training and Research Hospital
-
-
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 2ZN
- Werving
- Aberdeen Royal Infirmary
-
Birmingham, Verenigd Koninkrijk, B9 5SS
- Werving
- Birmingham Heartlands Hospital
-
Bournemouth, Verenigd Koninkrijk, BH7 7DW
- Werving
- The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
-
London, Verenigd Koninkrijk, SW3 6JJ
- Werving
- Royal Marsden Hospital
-
London, Verenigd Koninkrijk, NW1 2PG
- Werving
- University College Hospital
-
Southampton, Verenigd Koninkrijk, SO16 6YD
- Werving
- Southampton General Hospital
-
-
-
-
Arkansas
-
Jonesboro, Arkansas, Verenigde Staten, 72401
- Werving
- St Bernards Medical Center
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095-3075
- Werving
- UCLA Department of Medicine Hematologyoncology
-
San Diego, California, Verenigde Staten, 92103-2106
- Werving
- Scripps Prebys Cancer Center
-
Whittier, California, Verenigde Staten, 90602
- Werving
- Pih Health Whittier Hospital
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80012-5405
- Werving
- Rocky Mountain Cancer Centers (Williams) Usor
-
Golden, Colorado, Verenigde Staten, 80401
- Werving
- Intermountain Health Lutheran Hospital Cancer Center of Colorado
-
-
Florida
-
Fort Myers, Florida, Verenigde Staten, 33912
- Werving
- Florida Oncology and Hematology
-
Jacksonville, Florida, Verenigde Staten, 32207-8432
- Werving
- Baptist Md Anderson Cancer Center
-
Weston, Florida, Verenigde Staten, 33331-3609
- Werving
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322-1013
- Werving
- Emory University Winship Cancer Institute
-
Atlanta, Georgia, Verenigde Staten, 30342
- Werving
- Northside Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70808-4365
- Werving
- Our Lady of the Lake Hospital
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20817-7847
- Werving
- American Oncology Partners of Maryland Pa
-
-
Michigan
-
Grand Rapids, Michigan, Verenigde Staten, 49503-2560
- Werving
- Corewell Health the Michigan Cancer Consortium
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55455-0341
- Werving
- University of Minnesota
-
-
Missouri
-
Chesterfield, Missouri, Verenigde Staten, 63017
- Werving
- St Lukes Center For Cancer Care
-
Springfield, Missouri, Verenigde Staten, 65807-5288
- Werving
- Oncology Hematology Associates
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59102-6746
- Werving
- St Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68130-2042
- Werving
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
-
-
New York
-
New York, New York, Verenigde Staten, 10065-6800
- Werving
- Memorial Sloan Kettering Cancer Center Mskcc
-
Shirley, New York, Verenigde Staten, 11967
- Werving
- New York Cancer and Blood Specialists
-
Westbury, New York, Verenigde Staten, 11590-5119
- Werving
- Optum Medical Care, Pc
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106-1716
- Werving
- University Hospitals
-
Dayton, Ohio, Verenigde Staten, 45415
- Werving
- Dayton Physician Network
-
-
Oregon
-
Eugene, Oregon, Verenigde Staten, 97401
- Werving
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Werving
- West Penn Hospital
-
York, Pennsylvania, Verenigde Staten, 17403-5049
- Werving
- Cancer Care Associates of York
-
-
Texas
-
Temple, Texas, Verenigde Staten, 76508-0001
- Werving
- Baylor Scott and White Health
-
Tyler, Texas, Verenigde Staten, 75702-7522
- Werving
- Texas Oncology Tyler
-
-
-
-
Busan Gwang'yeogsi
-
Seogu, Busan Gwang'yeogsi, Zuid -Korea, 49201
- Werving
- Dong A University Hospital
-
-
Daegu Gwang'yeogsi
-
Junggu, Daegu Gwang'yeogsi, Zuid -Korea, 41944
- Werving
- Kyungpook National University Hospital
-
-
Gyeonggi-do
-
IlsandongGu GoyangSi, Gyeonggi-do, Zuid -Korea, 10408
- Werving
- National Cancer Center (Korea)
-
-
Jeonnam-Gwangju S.M. City
-
HwasunGun, Jeonnam-Gwangju S.M. City, Zuid -Korea, 58128
- Werving
- Chonnam National University Hwasun Hospital
-
-
Seoul Teugbyeolsi
-
GangnamGu, Seoul Teugbyeolsi, Zuid -Korea, 06351
- Werving
- Samsung Medical Center
-
SeochoGu, Seoul Teugbyeolsi, Zuid -Korea, 06591
- Werving
- The Catholic University of Korea, Seoul St Marys Hospital
-
Seoul, Seoul Teugbyeolsi, Zuid -Korea, 03080
- Werving
- Seoul National University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
- Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
- Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI)
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Adequate liver function
- Adequate blood clotting function
Exclusion Criteria:
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 3 months
- Known central nervous system involvement
- Prior exposure to any BTK protein degraders
- Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy
- Clinically significant cardiovascular disease
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A: Tacabrutideg monotherapy
Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met |
Administered orally
Andere namen:
|
|
Actieve vergelijker: Arm B: Investigator's Choice
Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment. |
Administered orally Administered intravenously Administered intravenously Administered orally |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Tijdsspanne: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL). |
Approximately 36 Months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Survival (OS)
Tijdsspanne: Approximately 36 Months
|
OS is defined as time from the date of randomization to the date of death due to any cause. |
Approximately 36 Months
|
|
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
Tijdsspanne: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL for participants with prior exposure to ncBTKi. |
Approximately 36 Months
|
|
PFS by the Investigator Assessment
Tijdsspanne: Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL |
Approximately 36 Months
|
|
Overall Response Rate (ORR) by IRC and Investigator Assessment
Tijdsspanne: Approximately 36 Months
|
ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (Cri), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
Tijdsspanne: Approximately 36 Months
|
Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator |
Approximately 36 Months
|
|
Duration of Response (DOR) by IRC and Investigator Assessment
Tijdsspanne: Approximately 36 Months
|
DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Time to Next Anti-CLL/SLL Treatment (TTNT)
Tijdsspanne: Approximately 36 Months
|
TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment. |
Approximately 36 Months
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Tijdsspanne: Approximately 36 Months
|
Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. |
Approximately 36 Months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire -Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) and Physical Functioning Scales
Tijdsspanne: Approximately 24 Months
|
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). Higher scores in GHS and functional scales indicate better quality of life. |
Approximately 24 Months
|
|
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
Tijdsspanne: Approximately 24 Months
|
The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning. |
Approximately 24 Months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Study Director, BeOne Medicines
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Chronische ziekte
- Ziekte attributen
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Leukemie, B-cel
- Leukemie, Lymfoïde
- Leukemie
- Pathologische aandoeningen, tekenen en symptomen
- Hemische en lymfatische ziekten
- Leukemie, lymfatische, chronische, B-cel
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen
- Benzimidazolen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Koolwaterstoffen
- Zuren, acyclisch
- Carbonzuren
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Stikstofmosterdverbindingen
- Mosterdverbindingen
- Koolwaterstoffen, gehalogeneerd
- Butyrates
- Antilichamen, monoklonaal, van murine afgeleid
- Bendamustine Hydrochloride
- Rituximab
- venetoclax
- idelalisib
Andere studie-ID-nummers
- BGB-16673-302
- 2024-518893-15-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD-tijdsbestek voor delen
See plan description
IPD-toegangscriteria voor delen
See plan description
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .